589 related articles for article (PubMed ID: 28144701)
21. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.
Popp AW; Zysset PK; Lippuner K
Osteoporos Int; 2016 May; 27(5):1917-21. PubMed ID: 26694598
[TBL] [Abstract][Full Text] [Related]
22. Effects of bone remodeling agents following teriparatide treatment.
Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
[TBL] [Abstract][Full Text] [Related]
23. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
[TBL] [Abstract][Full Text] [Related]
24. Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis.
Popp AW; Varathan N; Buffat H; Senn C; Perrelet R; Lippuner K
Calcif Tissue Int; 2018 Jul; 103(1):50-54. PubMed ID: 29380013
[TBL] [Abstract][Full Text] [Related]
25. Suboptimal medication adherence may favor the progression of vertebral fractures in women with post-menopausal osteoporosis treated with denosumab.
Betella N; Biamonte E; Matarazzo C; Piccini S; Olivetti R; Cellini M; Lania AG; Mazziotti G
Minerva Endocrinol; 2020 Sep; 45(3):165-171. PubMed ID: 32186164
[TBL] [Abstract][Full Text] [Related]
26. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial.
McClung MR; Lewiecki EM; Geller ML; Bolognese MA; Peacock M; Weinstein RL; Ding B; Rockabrand E; Wagman RB; Miller PD
Osteoporos Int; 2013 Jan; 24(1):227-35. PubMed ID: 22776860
[TBL] [Abstract][Full Text] [Related]
27. A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk.
Nayak S; Greenspan SL
Osteoporos Int; 2019 Apr; 30(4):705-720. PubMed ID: 30623214
[TBL] [Abstract][Full Text] [Related]
28. The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results.
Silverman S; Miller P; Sebba A; Weitz M; Wan X; Alam J; Masica D; Taylor KA; Ruff VA; Krohn K
Osteoporos Int; 2013 Aug; 24(8):2309-17. PubMed ID: 23404615
[TBL] [Abstract][Full Text] [Related]
29. The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation.
Makras P; Appelman-Dijkstra NM; Papapoulos SE; van Wissen S; Winter EM; Polyzos SA; Yavropoulou MP; Anastasilakis AD
J Clin Endocrinol Metab; 2021 Sep; 106(10):e4155-e4162. PubMed ID: 33978745
[TBL] [Abstract][Full Text] [Related]
30. [Experience in using Prolia in patients with postmenopausal osteoporosis in clinical practice].
Skripnikova IA; Kosmatova OV; Abirova ES; Novikov VE; Murashko LM
Ter Arkh; 2017; 89(12. Vyp. 2):190-196. PubMed ID: 29488480
[TBL] [Abstract][Full Text] [Related]
31. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
Leder BZ; Tsai JN; Jiang LA; Lee H
Bone; 2017 May; 98():54-58. PubMed ID: 28286299
[TBL] [Abstract][Full Text] [Related]
32. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
33. Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis.
Niimi R; Kono T; Nishihara A; Hasegawa M; Kono T; Sudo A
Osteoporos Int; 2018 Mar; 29(3):769-772. PubMed ID: 29230512
[TBL] [Abstract][Full Text] [Related]
34. Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial.
Silverman S; Viswanathan HN; Yang YC; Wang A; Boonen S; Ragi-Eis S; Fardellone P; Gilchrist N; Lips P; Nevitt M; Palacios Gil-Antuñano S; Pavelka K; Revicki D; Simon J; Macarios D; Siris ES
Osteoporos Int; 2012 Apr; 23(4):1361-9. PubMed ID: 21769664
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of denosumab on back pain-related disability and quality-of-life in patients with vertebral fragility fractures.
Moretti A; de Sire A; Curci C; Toro G; Gimigliano F; Iolascon G
Curr Med Res Opin; 2019 Jan; 35(1):151-155. PubMed ID: 30406685
[No Abstract] [Full Text] [Related]
36. Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.
Fahrleitner-Pammer A; Papaioannou N; Gielen E; Feudjo Tepie M; Toffis C; Frieling I; Geusens P; Makras P; Boschitsch E; Callens J; Anastasilakis AD; Niedhart C; Resch H; Kalouche-Khalil L; Hadji P
Arch Osteoporos; 2017 Dec; 12(1):58. PubMed ID: 28643265
[TBL] [Abstract][Full Text] [Related]
37. Denosumab treatment lapses, discontinuation, and off-treatment fracture risk: A retrospective study of patients with osteoporosis in a real-world clinical setting.
Cruchelow KR; Peter ME; Chakrabarti A; Gipson HM; Gregory WT; DeClercq J; Choi L; Tanner SB
Bone; 2023 Dec; 177():116925. PubMed ID: 37797711
[TBL] [Abstract][Full Text] [Related]
38. Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study.
Everts-Graber J; Reichenbach S; Gahl B; Ziswiler HR; Studer U; Lehmann T
Bone; 2021 Mar; 144():115830. PubMed ID: 33359006
[TBL] [Abstract][Full Text] [Related]
39. Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy.
Migliaccio S; Francomano D; Romagnoli E; Marocco C; Fornari R; Resmini G; Buffa A; Di Pietro G; Corvaglia S; Gimigliano F; Moretti A; de Sire A; Malavolta N; Lenzi A; Greco EA; Iolascon G
J Endocrinol Invest; 2017 Dec; 40(12):1321-1326. PubMed ID: 28589380
[TBL] [Abstract][Full Text] [Related]
40. Postmenopausal Osteoporosis: A Clinical Review.
Watts NB
J Womens Health (Larchmt); 2018 Sep; 27(9):1093-1096. PubMed ID: 29583083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]